M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-07-11

Last Posted Date: 2020-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 115

Registration Number: NCT00499512

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
St. Luke's Episcopal Hospital, Houston, Texas, United States
🇺🇸
Lyndon B. Johnson General Hospital, Houston, Texas, United States

and more 1 locations

Cord Blood Expansion on Mesenchymal Stem Cells

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndrome

Interventions: Procedure: Cord Blood Infusion
Drug: Busulfan
Drug: Fludarabine
Drug: Rituximab
Other: ATG
Drug: Cyclophosphamide
Drug: Clofarabine
Radiation: Total Body Irradiation (TBI)
Drug: Melphalan
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Drug: G-CSF

First Posted Date: 2007-07-10

Last Posted Date: 2020-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 98

Registration Number: NCT00498316

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cognitive Training in Attenuating Attention Deficits/Child Treatment for Cancer

Active, not recruiting

Conditions: Leukemia
Lymphoma
Brain Tumor

Interventions: Behavioral: Cognitive Training Program
Other: Control Group

First Posted Date: 2007-07-10

Last Posted Date: 2020-12-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00498719

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Quantitative Diffusion and Fat Imaging of the Spine

Completed

Conditions: Osteoporosis

Interventions: Procedure: Magnetic Resonance Imaging

First Posted Date: 2007-07-10

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT00498277

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Depression and Adherence in Head and Neck Cancer

Active, not recruiting

Conditions: Head and Neck Cancer
Oropharyngeal Cancer

Interventions: Behavioral: Questionnaire
Behavioral: Depression Intervention

First Posted Date: 2007-07-10

Last Posted Date: 2024-03-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 185

Registration Number: NCT00498875

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Cytoxan
Drug: Nipent
Drug: Rituxan

First Posted Date: 2007-07-04

Last Posted Date: 2023-03-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT00496873

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Azacytidine and Valproic Acid in Patients With Advanced Cancers

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Azacitidine
Drug: Valproic Acid

First Posted Date: 2007-07-04

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 69

Registration Number: NCT00496444

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Proton Beam Therapy for Chondrosarcoma

Phase 2

Active, not recruiting

Conditions: Chondrosarcoma

Interventions: Procedure: Proton Beam Therapy

First Posted Date: 2007-07-04

Last Posted Date: 2024-03-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00496522

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

Phase 2

Completed

Conditions: Renal Cell Carcinoma
Kidney Cancer

Interventions: Drug: Capecitabine
Drug: Gemcitabine
Drug: Bevacizumab

First Posted Date: 2007-07-04

Last Posted Date: 2017-07-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT00496587

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast

Not Applicable

Completed

Conditions: Ductal Carcinoma In Situ

Interventions: Drug: Herceptin (Trastuzumab)

First Posted Date: 2007-07-04

Last Posted Date: 2020-09-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 69

Registration Number: NCT00496808

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy